ASSESSMENT OF THE CARDIOVASCULAR BENEFITS OF DAPAGLIFLOZIN IN SUB-CONTINENT PATIENTS UNDERGOING REHABILITATION WITH TYPE 2 DIABETES MELLITUS

Abstract

Background and purpose: Cardiovascular and Renal Complications are found as burden to Diabetes mellitus patients. SGL2 Transporters although dapagliflozin has shown cardiovascular benefits in clinical trials, real-world evidence in Indian hospitalized patients is limited. This clinical study aimed to evaluate the cardiorenal and metabolic outcomes associated with Dapagliflozin (sodium–glucose cotransporter 2-SGLT2 inhibitor,) in Indian hospitalized patients with Type 2 Diabetes Mellitus (T2DM).

Methodology: A total of 340 hospitalized South Indian patients were screened for eligibility in the present study, and 174 met the inclusion criteria, were enrolled in the study, and were included in the analysis.  Baseline demographic characteristics and key laboratory parameters related to cardiac, renal, and metabolic function were collected after Dapagliflozin therapy.  Data analysis was performed using SPSS version 20.0, employing descriptive and inferential statistical methods to evaluate the impact of Dapagliflozin on cardiorenal markers and glycaemic outcomes.

Results: Dapagliflozin therapy was significantly associated with improvements in cardiac function indices, renal health markers, and glycaemic control among the 174 participants (106 men and 68 women).  The observed beneficial enhancements indicate a positive relationship between dapagliflozin therapy and optimistic, favourable cardiorenal and metabolic outcomes in the inpatient rehabilitation context.

Conclusion: Dapagliflozin treatment significantly enhanced cardiac function, supported by improvement in renal health in hyperglycaemic patients with type 2 diabetes and concurrent cardiac impairment.  The current clinical study supports its therapeutic benefits for hospitalized, high-risk patients with T2DM and cardiac dysfunction.